Avidity Biosciences
Research, development, and manufacturing of drug candidates which include antibody-sirna complexes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $345m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 37 % | (1 %) | 4 % | 14 % | (9 %) | 88 % | 1225 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1266 %) | (1940 %) | (2442 %) | (3452 %) | (6201 %) | (3456 %) | (143 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1265 %) | (1886 %) | (2220 %) | (2958 %) | (5569 %) | (3479 %) | (208 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1085 % | 1631 % | 1998 % | 2786 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Avidity Biosciences is at the forefront of developing a new class of oligonucleotide-based therapies known as Antibody Oligonucleotide Conjugates (AOCs). These therapies are designed to address the limitations of current oligonucleotide treatments, enabling the targeting of previously undruggable tissues and cell types. The company leverages its proprietary AOC platform to engineer and develop these innovative therapeutics. Avidity's initial focus is on muscle tissue, with a muscle disease franchise comprising five programs. The company operates in the biotechnology sector, primarily serving patients with serious diseases. Avidity's business model revolves around the research, development, and eventual commercialization of its proprietary therapies. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies.
Keywords: oligonucleotide, AOCs, muscle disease, biotechnology, therapeutics, proprietary platform, monoclonal antibodies, serious diseases, tissue selectivity, healthcare breakthroughs.